KERYX BEGINS LEUKEMIA TRIAL

Keryx Biopharmaceuticals has initiated a Phase II, multicenter, clinical program to evaluate its investigational anticancer compound KRX-0401 as a treatment for leukemia.

The clinical trial will assess the objective response rate and evaluate the pharmacokinetics and safety and tolerability of KRX-0401 (perifosine) as a single agent in relapsed or refractory acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, high-risk myelodysplastic syndrome and chronic myeloid leukemia in the blastic phase.